Printed From:

25
of LOVENOX establishing
real-world experience in the U.S. across multiple patient types1

LOVENOX is a proven choice in anticoagulant therapy.

Proven outcomes:
Across 8 indications
With multiple patient types
With demonstrated safety
and efficacy
Prophylaxis of DVT
Prophylaxis of DVT

Medically ill patientsWith comorbidities

Abdominal surgery patients Including elective cancer surgery

Knee replacement surgery patients Elderly patients (≥65 years of age)

Hip replacement surgery patients Elderly patients (≥65 years of age)

Acute DVT
Acute DVT

Inpatient treatment With or without PE

Outpatient treatment of acute DVT Without PE

ACS Patients
ACS Patients

Prophylaxis of ischemic complication
in UA/NSTEMI
Age range from 25 to 94 years (median age 64 years)

Treatment of acute STEMI Hospitalized within 6 hours of onset

A generic identical to LOVENOX Learn about the authorized generic of LOVENOX—Enoxaparin Sodium Injection
from Winthrop.

>
Established safety
profile in specific
populations
  • No dose adjustments recommended for patients with mild (CrCl=50 to 80 mL/min) or moderate (CrCl=30 to 50 mL/min) renal impairment
  • Modified dosing for patients with severe renal impairment (CrCl <30 mL/min) across all indications
  • Elderly patients
  • Low-weight patients




Patient self-injection video If your patients are going home with LOVENOX
self-injectables, this video provides helpful instructions.

>
+
Important Safety Information
for LOVENOX®

Warning: spinal/epidural hematoma Epidural or spinal hematomas may occur in
patients who are anticoagulated with low